RevenueNet IncomeP/EP/SEBITDividendStocksMarket capitalizationDebtLiabilitiesEquityAAQSEmployeesROEROAROCE
Aeterna Zentaris - Stock

Aeterna Zentaris Revenue 2024

Aeterna Zentaris Revenue

4.39 M USD

Ticker

AEZS.TO

ISIN

CA0079754028

WKN

A1439Z

In 2024, Aeterna Zentaris's sales reached 4.39 M USD, a -2.49% difference from the 4.5 M USD sales recorded in the previous year.

The Aeterna Zentaris Revenue history

YEARREVENUE (undefined USD)GROSS MARGIN (%)
2025e8.1552,49
2024e4.3997,49
20234.595,06
20225.698,21
20215.398,11
20203.735,14
20190.520,00
201826.992,19
20170.9475,11
20160.9475,11
20150.5100,00
2014--
20136.298,39
20122.171,43
20114.795,74
201027.732,49
200963.273,89
200838.549,87
200741.368,77
200638.870,88
200544.881,70
20043381,52

Aeterna Zentaris Revenue, EBIT, Net Income

  • 3 years

  • 5 years

  • 10 years

  • Max

Revenue
EBIT
Net Income
Details

Revenue, EBIT and Profit

ⓘ

Understanding Revenue, EBIT, and Income

Gain insights into Aeterna Zentaris, a comprehensive overview of its financial performance can be obtained by analyzing the Revenue, EBIT, and Income chart. Revenue represents the total income generated by Aeterna Zentaris from its primary operations, showcasing the company’s ability to attract and retain clients. EBIT, or Earnings Before Interest and Taxes, indicates the company’s operational profitability, free from the influence of tax and interest expenses. The Income section reflects Aeterna Zentaris’s net earnings, an ultimate measure of its financial health and profitability.

Yearly Analysis and Comparisons

Observe the yearly bars to understand the annual performance and growth of Aeterna Zentaris. Compare the Revenue, EBIT, and Income to evaluate the company’s efficiency and profitability. A higher EBIT compared to the previous year suggests an improvement in operational efficiency. Likewise, an increase in Income indicates enhanced overall profitability. Analyzing the year-to-year comparison assists investors in understanding the company’s growth trajectory and operational efficiency.

Utilizing Expectations for Investment

The expected values for the forthcoming years offer investors a glimpse into Aeterna Zentaris’s anticipated financial performance. Analyzing these projections alongside historical data aids in making informed investment decisions. Investors can gauge the potential risks and returns, aligning their investment strategies accordingly to optimize profitability and mitigate risks.

Investment Insights

Leveraging the comparison between Revenue and EBIT helps in assessing Aeterna Zentaris’s operational efficiency, while the Revenue and Income comparison reveals the net profitability after accounting for all expenses. Investors can derive valuable insights by meticulously analyzing these financial parameters, laying the foundation for strategic investment decisions aimed at capitalizing on Aeterna Zentaris’s growth potential.

Aeterna Zentaris Revenue, EBIT and net profit per share

DateAeterna Zentaris RevenueAeterna Zentaris EBITAeterna Zentaris Net Income
2025e8.15 M undefined-3.36 M undefined-1.64 M undefined
2024e4.39 M undefined-17.22 M undefined-10.52 M undefined
20234.5 M undefined-18.01 M undefined-16.55 M undefined
20225.6 M undefined-15.2 M undefined-22.7 M undefined
20215.3 M undefined-8.7 M undefined-8.4 M undefined
20203.7 M undefined-6.1 M undefined-5.1 M undefined
2019500,000 undefined-9.5 M undefined-6 M undefined
201826.9 M undefined9.8 M undefined4.2 M undefined
2017900,000 undefined-23.1 M undefined-16.8 M undefined
2016900,000 undefined-29.5 M undefined-25 M undefined
2015500,000 undefined-34.9 M undefined-50.1 M undefined
20140 undefined-34.9 M undefined-16.6 M undefined
20136.2 M undefined-27.5 M undefined6.8 M undefined
20122.1 M undefined-29.7 M undefined-20.4 M undefined
20114.7 M undefined-31.7 M undefined-27.1 M undefined
201027.7 M undefined-24.8 M undefined-28.5 M undefined
200963.2 M undefined-24 M undefined-24.7 M undefined
200838.5 M undefined-62.4 M undefined-59.8 M undefined
200741.3 M undefined-34.9 M undefined-33.1 M undefined
200638.8 M undefined-23.8 M undefined33.4 M undefined
200544.8 M undefined-9 M undefined10.6 M undefined
200433 M undefined-5.3 M undefined-3.4 M undefined

Aeterna Zentaris stock margins

The Aeterna Zentaris margin analysis displays the gross margin, EBIT margin, as well as the profit margin of Aeterna Zentaris. The EBIT margin (EBIT/sales) indicates the percentage of sales that remains as operating profit. The profit margin shows the percentage of sales that remains for Aeterna Zentaris.

  • 3 years

  • 5 years

  • 10 years

  • Max

Gross margin
EBIT margin
Profit margin
Details

Margin

ⓘ

Understanding Gross Margin

The gross margin, expressed as a percentage, delineates the gross profit made from the Aeterna Zentaris's sales revenue. A higher gross margin percentage indicates that the Aeterna Zentaris retains more revenue after accounting for the costs of goods sold. Investors use this metric to gauge financial health and operational efficiency, as well as to compare it with competitors and industry averages.

EBIT Margin Analysis

EBIT margin represents the Aeterna Zentaris's earnings before interest and taxes. Analyzing the EBIT margin over different years provides insights into the operational profitability and efficiency, excluding the effects of financial leverage and tax structure. A growing EBIT margin over the years signifies improving operational performance.

Revenue Margin Insights

The revenue margin demonstrates the Aeterna Zentaris's total revenue generated. When comparing the revenue margin year over year, investors can gauge the Aeterna Zentaris's growth and market expansion. It is essential to compare the revenue margin with the gross and EBIT margins to understand the cost and profit structures better.

Interpreting Expectations

The expected values for gross, EBIT, and revenue margins provide future financial outlook of the Aeterna Zentaris. Investors should compare these expectations with historical data to understand potential growth and risk factors. It is crucial to consider the underlying assumptions and methodologies used in projecting these expected values to make informed investment decisions.

Comparative Analysis

Comparing the gross, EBIT, and revenue margins, both yearly and over multiple years, enables investors to perform a comprehensive analysis of the Aeterna Zentaris's financial health and growth prospects. Evaluating the trends and patterns in these margins helps in identifying strengths, weaknesses, and potential investment opportunities.

Aeterna Zentaris Margin History

Aeterna Zentaris Gross marginAeterna Zentaris Profit marginAeterna Zentaris EBIT marginAeterna Zentaris Profit margin
2025e95.06 %-41.21 %-20.12 %
2024e95.06 %-392.6 %-239.95 %
202395.06 %-400.36 %-367.99 %
202298.21 %-271.43 %-405.36 %
202198.11 %-164.15 %-158.49 %
202035.14 %-164.86 %-137.84 %
201920 %-1,900 %-1,200 %
201892.19 %36.43 %15.61 %
201795.06 %-2,566.67 %-1,866.67 %
201695.06 %-3,277.78 %-2,777.78 %
2015100 %-6,980 %-10,020 %
201495.06 %0 %0 %
201398.39 %-443.55 %109.68 %
201271.43 %-1,414.29 %-971.43 %
201195.74 %-674.47 %-576.6 %
201032.49 %-89.53 %-102.89 %
200973.89 %-37.97 %-39.08 %
200849.87 %-162.08 %-155.32 %
200768.77 %-84.5 %-80.15 %
200670.88 %-61.34 %86.08 %
200581.7 %-20.09 %23.66 %
200481.52 %-16.06 %-10.3 %

Aeterna Zentaris Aktienanalyse

What does Aeterna Zentaris do?

Aeterna Zentaris Inc. is a Canadian company that has been operating in the pharmaceutical industry since 1991. The company is headquartered in Quebec City, Canada and focuses on the development and commercialization of drugs for the treatment of cancer and hormonal disorders. The company started as a small biotech company called "Aeterna Laboratories" that focused on the research of growth hormones and hormonal disorders. In the late 90s, it merged with a German company called "Zentaris GmbH" that specialized in medical diagnostics and chemicals, creating Aeterna Zentaris AG, which was later renamed Aeterna Zentaris Inc. The company has acquired several companies and expanded its portfolio of drugs and treatment options. Aeterna Zentaris is a biopharmaceutical company engaged in preclinical and clinical development of therapeutics. The company's main strategy is to develop and promote innovative and differentiating drug candidates. It works closely with leading academic institutions, researchers, and other companies to advance the development of its products. Aeterna Zentaris has a diversified portfolio of drug candidates in various stages of clinical development. It has two main divisions: cancer treatment and hormonal disorders. The company focuses on developing cancer therapeutics for various types of cancers and also on the treatment of hormonal disorders, including diabetes, growth problems, hormonally related cancers, and menopause. Some of the company's important products include Macrilen, which is used for diagnosing growth hormone deficiency, Zoptrex, which is intended for the treatment of endometrial cancer, and Perifosine, a drug candidate for advanced colorectal cancer. Aeterna Zentaris has established itself as a leading biotech company in the field of cancer and hormone therapy. It has a diverse portfolio of drug candidates in different stages of clinical development. The company collaborates with researchers, medical institutions, and other companies to develop innovative and differentiating drug candidates. Aeterna Zentaris ist eines der beliebtesten Unternehmen auf Eulerpool.com.

Revenue Details

Understanding Aeterna Zentaris's Sales Figures

The sales figures of Aeterna Zentaris originate from the total revenue accrued from goods sold or services provided during a specific time period. These numbers are a direct reflection of the company’s ability to translate its products or services into revenue, indicating the demand and market presence.

Year-to-Year Comparison

Analyzing Aeterna Zentaris’s yearly sales data offers insights into the company’s growth and stability. An increase in sales suggests a growing demand for its offerings, efficient marketing, or expansion into new markets. Conversely, a decline might indicate market saturation, increased competition, or less effective strategies.

Impact on Investments

Investors often scrutinize Aeterna Zentaris's sales data to evaluate its financial health and growth prospects. Consistent sales growth can be a promising indicator of the company’s profitability and potential return on investment, influencing stock prices and investor confidence.

Interpreting Sales Fluctuations

Increases in Aeterna Zentaris’s sales indicate market growth, innovation, or effective marketing, often leading to a surge in stock prices. A decline, however, can signal challenges requiring strategic adjustments to enhance market share and profitability.

Frequently Asked Questions about Aeterna Zentaris Stock

How much revenue did Aeterna Zentaris generate this year?

Aeterna Zentaris has achieved a revenue of 4.39 M USD this year.

How much was the turnover of the company Aeterna Zentaris compared to the previous year?

The revenue of Aeterna Zentaris has increased by -2.49% decreased compared to the previous year.

What does revenue mean for investors?

The revenue of a company is an important indicator of its financial performance and attractiveness for investors.

Which factors influence the revenue of Aeterna Zentaris?

The revenue of Aeterna Zentaris is influenced by various factors, including the demand for its products and services, market conditions, and prices.

How is the revenue of Aeterna Zentaris measured?

Revenue is typically measured in units referring to the sale of goods and services provided by the company.

How does an increase in sales affect investments?

An increase in revenue can prompt investors to invest more money in the company as it serves as a positive signal for its financial performance and growth prospects.

What are the possible risks associated with a declining revenue?

A decline in revenue can prompt investors to invest less money in the company, as it is a negative signal for its financial performance and growth prospects.

Why is the sales revenue of Aeterna Zentaris so important for investors?

The revenue of Aeterna Zentaris is an important indicator of financial performance and attractiveness for investors.

What strategic measures can a company take to increase revenue?

A company can take various strategic measures to increase revenue, including developing new products and services, introducing new pricing models, and expanding into new markets.

How much dividend does Aeterna Zentaris pay?

Over the past 12 months, Aeterna Zentaris paid a dividend of . This corresponds to a dividend yield of about . For the coming 12 months, Aeterna Zentaris is expected to pay a dividend of 0 USD.

What is the dividend yield of Aeterna Zentaris?

The current dividend yield of Aeterna Zentaris is .

When does Aeterna Zentaris pay dividends?

Aeterna Zentaris pays a quarterly dividend. This is distributed in the months of .

How secure is the dividend of Aeterna Zentaris?

Aeterna Zentaris paid dividends every year for the past 0 years.

What is the dividend of Aeterna Zentaris?

For the upcoming 12 months, dividends amounting to 0 USD are expected. This corresponds to a dividend yield of 0 %.

In which sector is Aeterna Zentaris located?

Aeterna Zentaris is assigned to the 'Health' sector.

Wann musste ich die Aktien von Aeterna Zentaris kaufen, um die vorherige Dividende zu erhalten?

To receive the latest dividend of Aeterna Zentaris from 7/3/2024 amounting to 0 USD, you needed to have the stock in your portfolio before the ex-date on 7/3/2024.

When did Aeterna Zentaris pay the last dividend?

The last dividend was paid out on 7/3/2024.

What was the dividend of Aeterna Zentaris in the year 2023?

In the year 2023, Aeterna Zentaris distributed 0 USD as dividends.

In which currency does Aeterna Zentaris pay out the dividend?

The dividends of Aeterna Zentaris are distributed in USD.

Stock savings plans offer an attractive way for investors to build wealth over the long term. One of the main advantages is the so-called cost-average effect: by regularly investing a fixed amount in stocks or stock funds, you automatically buy more shares when prices are low, and fewer when they are high. This can lead to a more favorable average price per share over time. In addition, stock savings plans allow small investors access to expensive stocks, as they can participate with small amounts. Regular investment also promotes a disciplined investment strategy and helps to avoid emotional decisions, such as impulsive buying or selling. Furthermore, investors benefit from the potential appreciation of the stocks as well as from dividend distributions, which can be reinvested, enhancing the compounding effect and thus the growth of the invested capital.

The Aeterna Zentaris stock can be added to a savings plan with the following providers: Trade Republic

Andere Kennzahlen von Aeterna Zentaris

Our stock analysis for Aeterna Zentaris Revenue stock includes important financial indicators such as revenue, profit, P/E ratio, P/S ratio, EBIT, as well as information on dividends. We also assess aspects such as stocks, market capitalization, debt, equity, and liabilities of Aeterna Zentaris Revenue. If you are looking for more detailed information on these topics, we offer comprehensive analyses on our subpages.